X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (101) 101
male (74) 74
middle aged (70) 70
aged (68) 68
female (62) 62
oncology (54) 54
index medicus (39) 39
human necessities (35) 35
agriculture (34) 34
animal husbandry (34) 34
devices for storing agricultural or horticultural produce (34) 34
fishing (34) 34
forestry (34) 34
hay or straw presses (34) 34
hunting (34) 34
processing of harvested produce (34) 34
trapping (34) 34
adult (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
cancer (28) 28
aged, 80 and over (27) 27
treatment outcome (26) 26
immunotherapy (25) 25
chemotherapy (24) 24
colorectal cancer (22) 22
cancer therapies (20) 20
surgery (20) 20
expression (19) 19
metastasis (19) 19
gastric cancer (18) 18
conveying (16) 16
handling thin or filamentary material (16) 16
machines, apparatus or devices for, or methods of, packagingarticles or materials (16) 16
packing (16) 16
performing operations (16) 16
storing (16) 16
transporting (16) 16
tumors (16) 16
unpacking (16) 16
medical prognosis (15) 15
stomach cancer (15) 15
pancreatic cancer (14) 14
stomach neoplasms - drug therapy (14) 14
stomach neoplasms - pathology (14) 14
colorectal neoplasms - drug therapy (13) 13
lymphocytes (13) 13
prognosis (13) 13
animals (12) 12
carcinoma (12) 12
care and treatment (12) 12
drug combinations (12) 12
health aspects (12) 12
neoplasm staging (12) 12
research (12) 12
cells (11) 11
genetic aspects (11) 11
identification (11) 11
mice (11) 11
biomarkers (10) 10
combined modality therapy (10) 10
esophageal cancer (10) 10
gene expression (10) 10
survival (10) 10
analysis (9) 9
antineoplastic agents - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
breast-cancer (9) 9
clinical trials (9) 9
colorectal neoplasms - immunology (9) 9
cytotoxicity (9) 9
esophageal neoplasms - pathology (9) 9
esophageal neoplasms - surgery (9) 9
hepatectomy (9) 9
lentinan (9) 9
medicine, research & experimental (9) 9
peptides (9) 9
proteins (9) 9
stomach neoplasms - surgery (9) 9
articles (8) 8
cell line, tumor (8) 8
development and progression (8) 8
fluorouracil (8) 8
hepatocellular-carcinoma (8) 8
liver neoplasms - secondary (8) 8
multivariate analysis (8) 8
original (8) 8
antigens (7) 7
cisplatin - administration & dosage (7) 7
colorectal neoplasms - genetics (7) 7
colorectal neoplasms - pathology (7) 7
combination (7) 7
deoxycytidine - analogs & derivatives (7) 7
drug therapy (7) 7
gemcitabine (7) 7
lentinan - administration & dosage (7) 7
lymphatic metastasis (7) 7
medicine & public health (7) 7
mice, inbred balb c (7) 7
organoplatinum compounds - therapeutic use (7) 7
original article (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 886 - 893
Journal Article
Cancer Science, ISSN 1347-9032, 03/2017, Volume 108, Issue 3, pp. 455 - 460
Cetuximab has activity against colorectal cancers. Recent studies demonstrated that cetuximab induces antibody‐dependent cell‐mediated cytotoxicity via immune... 
cetuximab | immune‐enhancing effect | colorectal cancer | TILs | Antibody‐dependent cellular cytotoxicity | immune-enhancing effect | Antibody-dependent cellular cytotoxicity | LEUCOVORIN | MULTICENTER PHASE-II | COMBINATION | FLUOROURACIL | PROGNOSTIC VALUE | FOLFIRI | ONCOLOGY | OXALIPLATIN-BASED CHEMOTHERAPY | 1ST-LINE THERAPY | INFLAMMATORY RESPONSE | T-CELLS | Bevacizumab - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - pathology | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | CD56 Antigen - metabolism | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Liver Neoplasms - drug therapy | Inflammation - immunology | CD3 Complex - metabolism | CD8 Antigens - metabolism | Colorectal Neoplasms - immunology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Medical research | Immune response | Liver | Colorectal cancer | Antibodies | Metastasis | Antineoplastic agents | Viral antibodies | Antimitotic agents | Chemotherapy | Cell death | Immunotherapy | Medicine, Experimental | Cancer | Peptides | CD8 antigen | Colorectal carcinoma | Cytotoxicity | Cancer therapies | Metastases | Epidermal growth factor | Lymphocytes | CD56 antigen | Lymphoid cells | Immunoglobulins | Research & development--R&D | Invasiveness | CD3 antigen | Inflammation | Immunogenicity | Hepatocytes | Microenvironments | Apoptosis | Original
Journal Article
Cancer Science, ISSN 1347-9032, 01/2017, Volume 108, Issue 1, pp. 73 - 80
We previously conducted a phase I clinical trial combining the HLA‐A*2402‐restricted KIF20A‐derived peptide vaccine with gemcitabine for advanced pancreatic... 
phase II | CTL | Advanced pancreatic cancer | peptide cocktail | immunotherapy | PLUS GEMCITABINE | DENDRITIC CELLS | EPITOPE-PEPTIDES | HEPATOCELLULAR-CARCINOMA | IN-VITRO | ONCOLOGY | COLORECTAL-CANCER | GENOME-WIDE ANALYSIS | GENE-EXPRESSION | HUMAN-MELANOMA | 1ST-LINE THERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | HLA-A24 Antigen - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vascular Endothelial Growth Factor Receptor-2 - immunology | Peptides - administration & dosage | Pancreatic Neoplasms - drug therapy | Cancer Vaccines - therapeutic use | Deoxycytidine - therapeutic use | Time Factors | Vascular Endothelial Growth Factor Receptor-1 - immunology | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | T-Lymphocytes, Cytotoxic - immunology | HLA-A24 Antigen - immunology | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Peptides - immunology | Cancer Vaccines - adverse effects | Pancreatic Neoplasms - genetics | Treatment Outcome | Kinesin - immunology | Cancer Vaccines - immunology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pancreatic Neoplasms - immunology | Aged | Deoxycytidine - analogs & derivatives | Peptides - adverse effects | Peptides - therapeutic use | Nuclear magnetic resonance--NMR | Gemcitabine | Peptides | Vaccination | Clinical trials | Cytotoxicity | Lymphocytes T | Vaccines | Cancer therapies | Cancer vaccines | Immunology | Lymphocytes | Immunotherapy | Genotypes | Antigens | Immunization | Cell survival | Immune response | Research & development--R&D | Mortality | Injection | Patients | Disease control | Chemotherapy | Immunogenicity | Medical prognosis | Pancreatic cancer | Response rates | Histocompatibility antigen HLA | Original
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1825 - 1829
Journal Article
Cancer Science, ISSN 1347-9032, 11/2017, Volume 108, Issue 11, pp. 2229 - 2238
Journal Article
Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1599 - 1609
Journal Article
Journal Article
Gastric Cancer, ISSN 1436-3291, 9/2018, Volume 21, Issue 5, pp. 811 - 818
Journal Article